A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the drug levels and biomarkers in the body and the
safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the
study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4
treatments will be placebo, which does not contain an active ingredient. The study
participation includes in-patient and out-patient days.